Iron Status Biomarkers and Cardiovascular Risk by Vaquero, María Pilar et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Iron Status Biomarkers and Cardiovascular Risk
María Pilar Vaquero,  Ángel García-Quismondo,
Francisco J. del Cañizo and
Francisco J. Sánchez-Muniz
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.69040
Abstract
Both iron excess and deficiency may be related to oxidative stress. Serum ferritin, the main 
marker of iron status, and hepcidin, the key regulator of iron metabolism, are increased in 
inflammation states and their links with insulin resistance are emerging topics. We have 
reviewed the role of iron deficiency/overload in cardiovascular risk, including our own 
results. Most studies deal with the association between iron deposition in tissues and car-
diovascular risk, while decreased iron status is predominantly related to protection against 
atherosclerosis and coronary heart disease. Less information is available on the role of 
iron status in type 2 diabetes mellitus (T2DM). Serum ferritin is positively correlated with 
several indicators of cardiovascular risk in healthy adults and diabetics, thus excess body 
iron is related to cardiometabolic alterations including vascular and heart damage, central 
obesity, and metabolic syndrome. Our data in an ample sample of T2DM adults suggest 
that body iron stores, evaluated as ferritin, are clearly related with some key markers 
of the so-called lipidic triad (high triglyceride and low high-density lipoprotein (HDL) 
cholesterol) levels together with the presence of small and dense low-density lipoprotein 
particles which also is in the frame of the dysmetabolic iron overload syndrome.
Keywords: iron, cardiovascular diseases, iron overload, iron deficiency, oxidative 
stress, hepcidin, ferritin, insulin, Type 2 diabetes Mellitus, lipidic triad, biomarker, 
dysmetabolic iron overload syndrome, human
1. Introduction
1.1. Iron metabolism and regulation
Iron is essential for life as it plays a central role in many biological processes that involve 
oxygen transport and storage and oxidative metabolism. This essential metal participates in 
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many  enzymatic systems such as those involved in DNA, RNA, and protein syntheses and 
in the regulation of gene expression, electron transport in the mitochondria, neurotransmitter 
metabolism, vitamin D activation, and cholesterol catabolism through the 7α-hydroxylase 
linked to isoenzyme P450 cytochrome (CYP7A1c) that depends on iron and converts choles-
terol to colic acid [1, 2].
Most of the functional iron in the body is present in the form of hemoglobin and myoglobin, 
and minor levels are part of a variety of heme and non-heme enzymes; the remainder is stored 
and mobilized when physiological demands are increased. The existence of two ionic forms, 
Fe2+ and Fe3+, means that this nutrient is capable to serve both as an electron donor and as an 
acceptor, which makes iron essential but also a potential toxic. In order to limit the amount 
of free ions that can induce free radical formation, iron is transported, bound to proteins, and 
stored intracellularly within a macro-protein structure, ferritin.
Iron in food is present in two forms, inorganic iron and heme iron. These forms are absorbed 
by different mechanisms; the heme route is highly efficient but contributes only to about 
10–15% of total dietary iron. Non-heme iron bioavailability is enhanced principally by animal 
tissue and ascorbic acid, whereas phytic acid and polyphenols are the main inhibitors [1, 3–6]. 
Solubility is an important factor for iron uptake; soluble ferrous iron is transported by the 
divalent metal transporter (DMT1) located at the luminal side of the duodenal membrane. 
However, this is not as simple; on the one hand, this carrier is not iron specific and there is 
competition from other divalent metals, such as calcium [7] and zinc, and on the other hand, 
ferric ion can be also transported either after reduction to ferrous by the duodenal cytochrome 
B or by interaction to mucins and subsequent association with β3-integrin and mobilferrin 
that cross the membrane and internalize iron in the cytosol [8, 9].
It is important to emphasize that iron absorption is tightly controlled, but once absorbed there 
are no excretion mechanisms. In contrast, iron recycling in the body is highly efficient; senes-
cent erythrocytes are phagocytosed by macrophages in the liver, spleen, and bone marrow. 
Under normal conditions, only about 10% of the 10–18 mg/day-ingested iron is absorbed. 
However, during late pregnancy (from 6 to 9 months), in order to cover fetal demands for 
growth and erythropoiesis, iron absorption increases to 25% [10]. The main serum transporter 
is transferrin, a protein capable of binding 1 or 2 ferric ions that are released into cells by the 
transferrin receptor (TfR1). Iron recycling involves 10–20 times greater iron flux than intes-
tinal absorption, that makes approximately 20–25 mg of iron circulating daily, an amount 
sufficient to ensure erythropoiesis needs. This role is played by macrophages in the spleen, 
bone marrow, and liver (Küpffer cells) [11]. Iron losses are due to intestinal desquamation and 
menstruation and should balance absorbed amounts (average 1–2 mg/day). However, hemor-
rhages, intense menstrual blood loss [12], pregnancy, and intense growth are frequent causes 
of iron deficiency anemia (IDA).
In iron overload conditions, such as hereditary hemochromatosis, transferrin becomes saturated 
with iron and the excess occurs as non-transferrin-bound iron (NTBI) that may be toxic [13].
The discovery of the intracellular iron regulatory proteins and that of the key regulator, hepci-
din, has triggered a revolution in iron metabolism research. Hepcidin, now accepted as a true 
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hormone, was initially named liver-expressed antimicrobial peptide (LEAP-1) and shortly 
later renamed as hepcidin because it is expressed in the liver (hep-) and exhibits antimicrobial 
activity (-cidin) [14, 15].
Figure 1 shows a scheme of the role of hepcidin on systemic iron homeostasis under con-
ditions of high or low iron level. Hepatic hepcidin synthesis is stimulated, secreted into 
the circulation, and released into tissues when iron levels are high. In different cells but 
mainly in hepatocytes, enterocytes, and macrophages, hepcidin inhibits iron export, thus 
decreases absorption, recycling, and circulation of iron. This hormone therefore is a nega-
tive regulator of iron status. The mechanism of action is binding to its receptor, the cellu-
lar iron exporter ferroportin (FPN), and subsequent internalization and degradation of the 
hepcidin-ferroportin complex. In contrast, under physiological or pathological situations 
of low iron levels, hepcidin synthesis is minimized resulting in an enhanced iron flux from 
liver and macrophages stores and an increased transport through the duodenal basolateral 
membrane.
The gene-encoding hepcidin, HAMP, is expressed primarily in hepatocytes, although there is 
also evidence of expression in duodenal enterocytes, liver Kupffer cells, splenic macrophages, 
and placental syncytiotrophoblasts [16]. Sequencing of HAMP reveals several mutations that 
are either not functional [17] or related to a rare form of hemochromatosis [18] indicating 
low variability and that this gene is highly conserved in humans while the common iron 
metabolism alterations, either iron deficiency or hemochromatosis, have been associated with 
polymorphisms in other genes [19–23].
Figure 1. Role of hepcidin in systemic iron homeostasis. (A) High iron level conditions. Hepatic hepcidin expression 
and circulating hepcidin levels are increased; in hepatocytes, enterocytes, and macrophages, hepcidin is bound to the 
complex ferroportin-hephaestin and ferroportin is internalized and degraded; consequently, iron efflux is inhibited. (B) 
Low iron level conditions. Hepatic hepcidin synthesis is inhibited and serum hepcidin levels are negligible; consequently, 
iron crosses the membrane and is delivered into the circulation and transported to tissues by transferrin that is highly 
saturated (FNP: ferroportin; HP: hephaestin). Modified from Blanco-Rojo R. [24].
Iron Status Biomarkers and Cardiovascular Risk
http://dx.doi.org/10.5772/intechopen.69040
99
On the other hand, hepcidin regulation is a very active field. Many stimuli affect hepcidin 
transcription; the main factors are iron level, as explained above; inflammation, as hepci-
din behaves as an acute phase protein; hypoxia, through the hypoxia inducible factor; and 
erythropoiesis signals. The details of hepcidin regulation and intracellular iron regulatory 
proteins involved in transcription are far beyond this revision and have been reviewed by 
others [16, 19, 24–27].
1.2. Role of macrophages in iron recycling
Hemoglobin in erythrocytes constitutes the major iron pool of the body. Senescent or dam-
aged erythrocytes are phagocytosed by macrophages in the spleen, bone marrow, and liver. 
This activity is very efficient, as daily 20–25 mg of iron is delivered from macrophages into 
circulation and recycled, and the amount of iron that has to be absorbed for body functions is 
only 1–2 mg per day. Moreover, macrophages can work as a reservoir and participate in iron 
homeostasis [11].
Figure 2 shows the erythrophagocytic activity of macrophages. Once the macrophage detects 
an alteration or damage in the erythrocyte, the phagocytosis process is triggered. First, the 
erythrocyte is incorporated into the phagosome and heme is released. Then, heme is catab-
olized by hemoxigenase-1, and carbon monoxide, biliverdin, and Fe2+ are released. Fe2+ is 
transported across the phagosome membrane by DMT1 and natural resistance-associated 
Figure 2. Erythrophagocytic activity of macrophages. CO: carbon monoxide; HO-1: hemoxygenase-1; Bv: biliverdin; 
DMT-1: dimetal transporter-1; Nramp1: natural resistance-associated macrophage protein; FTN: ferroportin. Modified 
from Blanco-Rojo R. [24].
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macrophage protein (Nramp1). It seems that the presence of both transporters makes recy-
cling more efficient. If iron is not needed for erythropoiesis, it is stored as ferritin in the form 
of Fe3+. Finally, iron is released into the circulation via ferroportin and hephaestin (HP), and 
the iron is donated to transferrin to be reutilized [28].
2. Role of iron in oxidative status
The redox potential of iron, that is the switch between Fe2+ and Fe3+, is essential for many bio-
chemical reactions but is also a potential threat. Iron toxicity is based on the Fenton and Haber-
Weiss reaction, which generates •OH (hydroxyl radicals) from H2O2 (hydrogen peroxide) and superoxide (•O2−) in the presence of catalytic amounts of iron. The first step of the catalytic cycle involves reduction of ferric ion to ferrous:
  F  e 3+ + • O 2   −  → F  e 2+ +  O 2 (1)
The second step is:
  F  e 2+ +  H 2   O 2  → F  e 3+ + O  H − + •OH (2)
Net reaction:
  • O 2   − +  H 2   O 2  → •OH + O  H − +  O 2  (where Fe acts as a catalytic metal ) (3)
The catalytic action of iron also leads to the formation of organic reactive oxygen species 
(ROS), such as peroxyl radicals (ROO•), alkoxyl radicals (RO•), thiyl radicals (RS•), sulfonyl 
radicals (ROS•), thiyl peroxyl radicals (RSOO•), and disulfides (RSSR). Similarly, heme iron 
catalyzes the formation of ROS, via the formation of oxoferryl intermediates. In addition, fer-
rous iron can also contribute as a reactant to free radical generation [29].
It is worth mentioning that ROS are normally produced by the mitochondria aerobic metabo-
lism through the incomplete reduction of molecular oxygen. ROS can also be generated by the 
membrane-bound NADPH oxidase complex that is an important tool for the antimicrobial 
defense and is mainly expressed not only in phagocytic macrophages but also in neutrophils 
and other cell types.
ROS are highly reactive species and promote the oxidation of proteins, nucleic acids, and 
membrane lipids. Any increase in the ROS levels beyond the antioxidant capacity of the 
organism causes oxidative stress [29]. In this regard, in primary and secondary iron overload 
conditions, such as in hereditary hemochromatosis and thalassemia, respectively, oxidative 
stress is observed as the iron-binding capacity of transferrin gets saturated and high levels of 
non-transferrin-bound iron reach the cell, are internalized, and induce tissue damage [30, 31].
Excess iron is involved in the pathophysiology of chronic inflammation, Alzheimer disease, 
diabetes, atherosclerosis, and, generally, cardiovascular diseases (CVD).
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3. Iron excess and cardiovascular risk
3.1. The iron hypothesis
Early in the 1980s, Sullivan published in The Lancet the hypothesis that higher-stored iron in 
men and postmenopausal women compared to premenopausal women increase the risk of 
heart diseases and that iron deficiency is a protective factor [32]. This was supported by epi-
demiological studies; positive associations between serum ferritin (marker of iron stores), 
and the cholesterol transported by low-density lipoproteins (LDL-cholesterol) that were 
reported in men [33]. But other data do not support this hypothesis [34, 35] and the debate 
still continues. Our research group and others have reported that iron-deficient and anemic 
women present low lipid levels that increase during pharmacological treatment with iron 
salts, although final values are in normal range [36, 37]. Other studies coincide in the gender 
and age differences in iron metabolism and lipoprotein metabolism and the lower cardio-
vascular risk in women compared to men [38]. However, there may be several interacting 
factors. In this regard, estrogens are related to higher levels of cholesterol transported by 
high-density lipoproteins (HDL-cholesterol) and aldosterone that may partly explain lower 
atherosclerosis and hypertension risk [39]. However, age has been suggested to exert higher 
influence than hormones as estrogens explain about 25% of the phenotype differences 
related to cardiovascular risk, and thus menopausal women have higher cardiovascular risk 
than fertile women mainly due to age [40]. Studies in older men and women do not support 
the Sullivan’s hypothesis and are rather opposite, with a subgroup of individuals who have 
low iron stores and higher cardiovascular risk [41]. Likewise, our findings in an elderly 
population consuming a variant of the Mediterranean diet show that prevalence of anemia 
is higher than that of high ferritin [42].
Therefore, it is likely that iron is only one of the players in the pathophysiological process of 
cardiovascular diseases.
3.2. Iron excess and atherosclerosis
Atherosclerosis is a chronic inflammatory disease affecting the arterial intima [43, 44]. 
Endothelial dysfunction induces recruitment of LDL particles and blood monocytes that dif-
ferentiate into macrophages, phagocyte lipid material, and are transformed into foam cells [45]. 
The possibility that iron plays an interacting role emerges from its capacity to enhance the 
formation of ROS and LDL oxidation and its presence in macrophages, where a reservoir of 
intracellular iron may remain if body iron is high. In this regard, high iron levels hypothetically 
increase atherosclerosis risk.
However, there are many doubts on this hypothesis. Results from the ARIC study, carried 
out in the 1990s, did not find an association between ferritin values and LDL oxidation [43] or 
ferritin and asymptomatic carotid atherosclerosis [44]. Likewise, a recent systematic analysis 
by Hosseini [46] concludes that iron intake/status is not associated with carotid intima media 
thickness. In this issue, it could be speculated that the effect of iron is related to the “labile 
pool” or unbound iron more than to the total amount of iron in the body.
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Results from the MONICA study in France [47] show that carotid atherosclerosis was positively 
associated with serum ferritin in individuals free from subclinical inflammation. In another 
study [48], atherosclerotic plaque specimens, which were removed from carotids of patients as 
a stroke reduction strategy, were analyzed. The study compared symptomatic and asymptom-
atic plaques considering that stroke symptoms occur when carotid bifurcation plaque ruptures 
and clots move into the cerebral circulation. It has been assumed that iron accumulates in 
atherosclerosis plaques following plaque rupture and hemorrhage since phagocytosed eryth-
rocytes have been identified in plaque macrophages. It was found that in the symptomatic 
plaque (causing stenosis and cerebrovascular symptoms), iron is associated with the patient’s 
LDL-cholesterol level. Furthermore, iron is abundant in such unstable plaques within throm-
bus, in the presence of macrophages, and away from calcium and zinc, elements that co-local-
ize in areas of plaque mineralization. Finally, iron in asymptomatic plaque (causing stenosis 
but not neurological symptoms) was present as ferritin and was observed in association with 
CD68-positive macrophages.
Therefore, iron may be involved both in the initial step of atherosclerosis by activating LDL oxi-
dation and in the final step linked to the vessel lesion within the plaque. Interestingly, increas-
ing the iron levels in circulating macrophages do not increase atherosclerosis [49]. In a mouse 
model of atherosclerosis (ApoE-/-), mice were fed with a high-fat diet and their tissue iron was 
increased by parenteral iron administration and a genetic mutation in ferroportin [49]. Iron 
loading produced an iron level increase in macrophages, liver, and spleen and resulted in the 
activation of the macrophage antioxidant defenses and in the storage of iron in the form of fer-
ritin. Clearly, this regulation reduced NTBI and toxicity.
With the hypothesis that blood donation reduces cardiovascular risk by lowering body iron 
status, a study was done in 819 healthy blood donors in the Netherlands [50]. Data included 
blood donation frequency, body iron status parameters, and a measure of the carotid intima-
media thickness (CIMT). Body iron status was not related to CIMT, but CIMT was slightly 
and not significantly reduced in frequent donors. Therefore, blood donation might give some 
protection against atherosclerosis in individuals predisposed to accumulate iron in excess, 
but the mechanism may be independent of total body iron.
The possibility that heme instead of iron is the inductor of LDL oxidation has also been 
investigated [51, 52]. Heme oxygenase-1, the heme-catabolizing enzyme, is therefore cru-
cial for heme detoxification (see HO-1 in Figure 2). HO-1 induction results in an increase in 
free iron and ferritin upregulation, which means iron storage and protection of the cell [51]. 
Interestingly, a child with HO-1 deficiency showed elevated plasma heme levels, extensive 
LDL oxidation, severe endothelial damage, and accelerated atherosclerosis, and thus the pos-
sibility of a HO-1 therapy that mitigates some of the symptoms is a matter of research [52, 53].
3.3. Lessons from hemochromatosis and other iron overload disturbances
Type 1 hereditary hemochromatosis (HH) is a genetic disease defined as homozygous for 
the C282Y mutation of the HFE gene. This gene is located in chromosome 6 and encodes the 
major histocompatibility complex class I-like protein HFE. The prevalence of HH is approxi-
mately 0.1% in the population of Caucasian origin. However, low morbidity has been found 
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in HH and most of the C282Y +/+ have no iron overload phenotype or are asymptomatic until 
adulthood. Cash et al. [30] compared vascular function, biochemical endothelial markers, 
and antioxidant status between HH patients (C282Y homozygous and high serum-ferritin 
levels) and controls. Noninvasive pulse wave analysis and pulse wave velocity were applied 
to carotid and radial arteries to estimate endothelial dysfunction. They reported that male 
HH patients had higher pulse wave velocity; however, this effect disappeared after adjust-
ing for hypertension. In both sexes, HH was associated with diminished antioxidant levels 
but neither increase in lipid peroxidation nor alteration in the systemic inflammation marker 
(i.e., C-reactive protein) could be demonstrated [30]. Thus, controversy remains on the idea 
that cardiovascular risk is high in hemochromatosis patients [54].
Iron overload is usually a complication of thalassemia, particularly in patients who require 
red blood cell transfusions. Among the three types of thalassemia, thalassemia intermedia is 
characterized by ineffective erythropoiesis, anemia, medullary expansion, and extramedul-
lary hematopoiesis. In contrast to HH, thalassemic patients show a proatherogenic biochemi-
cal phenotype which may contribute to enhance cardiovascular risks [31].
There are other iron overload pathological situations, where bone medulla is inefficient and 
iron overload results from repeated transfusions. In such syndromes, the amount of body 
iron can reach very high values and myocardial damage is the most frequent collateral effect 
of the treatment. In these cases, iron chelation therapy may result in higher quality of life and 
reduction of cardiac events [55].
4. Iron deficiency anemia and cardiovascular risk
Oxidative stress results from disequilibrium between oxidants and antioxidants. While iron 
excess may be involved in the generation of ROS, as commented above, anemia due to iron 
deficiency anemia (IDA) may affect the functioning of many enzymatic systems (cytochromes, 
catalases, hydroxylases, etc.) related to immunity, antioxidant status, and DNA integrity, 
among others [56].
In this regard, Aslan et al. [57] compared total plasma antioxidant capacity and lymphocyte DNA 
damage between two groups of IDA and control adults and concluded that both oxidative stress 
and DNA damage increased in IDA. In another study, four groups were compared: patients 
recently diagnosed with IDA who were not receiving any treatment at the beginning of the study; 
patients with IDA at the sixth week of an iron-replacement program (considered the time of 
hemoglobin normalization); patients with IDA at the end of the iron-replacement treatment (time 
of saturation of body iron stores); and age- and sex-matched healthy controls. Results show that 
untreated IDA patients present high lipid peroxidation, assessed by plasma malondialdehyde, 
and low activities of the antioxidant enzymes glutathione peroxidase, superoxide dismutase, and 
catalase and that the values did not differ between the sixth week and the end of the treatment, 
suggesting that recovery from IDA reduces oxidative stress [58]. Unfortunately, in these studies, 
the changes within a patient were not analyzed. In animal models of IDA, where all experimental 
conditions are controlled, high oxidative stress and DNA damage were not demonstrated [59, 60].
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Another aspect that has been studied is the possible changes in lipid levels in IDA. Old ani-
mal studies reported dyslipidemia with altered triglycerides and total cholesterol in serum. 
However, in most animal experiments, there were important confounders. For instance, 
iron deficiency induces low appetite and a reduction in food intake that often was not 
adequately controlled. In this regard, there are inconsistent results, but clearly the direc-
tion of change was toward reduction in circulating lipids and profound modifications in 
lipoprotein metabolism [61].
In humans, our research group found low values of total cholesterol, HDL-cholesterol, glu-
cose, and uric acid in IDA women at fertile age, which significantly increased during anemia 
recovery [36]. These results coincide with that of others who also reported low serum triglycer-
ides [62] and LDL-cholesterol [63]. It is noteworthy that despite significant increases after treat-
ment, the observed lipid values were very low in the severe anemic patients from these studies 
and still did not reach levels of non-anemic controls after recovery (reported mean values were 
approximately 150–170 mg/dL for total cholesterol and 60–70 mg/dL for triglycerides).
The above results can be explained by inhibition of lipid biosynthesis due to iron deficiency. 
Kamei et al. [64] performed a transcriptome analysis to determine the effects of iron defi-
ciency on hepatic gene expression. Rats on an iron-deficient diet were compared with rats 
pair-fed a control diet with a normal iron level. In agreement with human studies, these 
authors observed that iron deficiency decreases cholesterol and triglycerides in serum and 
liver. In addition, they found that serum glucose and insulin increased. Expressions of genes 
encoding gluconeogenic enzymes were upregulated, lactate was increased, and the urea cycle 
was activated. These results are explained by the insufficiency of iron for its enzymatic func-
tions and the situation of hypoxia due to anemia. Nevertheless, the results of high glucose 
and insulin do not agree with human observations.
Iron deficiency may affect cardiovascular health by indirect mechanisms. In this regard, iron 
participates in the hydroxylation of vitamin D to the active metabolites, 25 hydroxyvitamin D 
and 1,25-hydroxyvitamin D, and vitamin D acts as an antioxidant and may have protective 
cardiovascular effects, decreasing LDL-cholesterol, and blood pressure [37]. Moreover, iron 
supplementation alone increases vitamin B12 and folic acid levels [36]. This is attributed to a 
general increase in intestinal mucosa that favors nutrient absorption.
5. Dysmetabolic iron, type 2 diabetes, and cardiometabolic alterations
5.1. Iron excess and type 2 diabetes mellitus (T2DM)
T2DM is the most common and an ever-increasing form of diabetes [65]. It is characterized by dis-
orders in insulin secretion or action either of which maybe the predominant feature. The associa-
tion between iron overload and T2DM came from the observation that the frequency of diabetes 
is increased in classic hereditary hemochromatosis [65]. A link between red meat consumption, 
one of the highest iron bioavailability source, and T2DM has been reported [66]. Moreover, some 
reports show a relationship between high ferritin and the risk of gestational diabetes [67].
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The positive association between iron excess and T2DM is feasible although the underlying 
mechanisms still remain to be fully determined. First, iron is a powerful pro-oxidant and 
catalyst molecule, which promotes the formation of hydroxyl radicals and could attack pan-
creatic β cells by increasing oxidative stress thus resulting in impaired insulin synthesis and 
secretion [68]. Second, iron excess can diminish insulin utilization in muscle tissue leading to a 
shift from glucose to free acid oxidation, which may result in enhanced insulin resistance [69]. 
Third, increasing free fatty acid, main substrate for hepatic gluconeogenesis, would provoke 
higher glucose production [69]. Thus, the possible mechanisms are insulin deficiency, insulin 
resistance, and hepatic dysfunction [70].
Several studies report an association between the heme iron intake and risk of T2DM. The 
prospective cohort within the Nurses’ Health Study found that higher intake of heme iron 
was associated with higher intake of fat (total and saturated), red meat, and protein and with 
lower intake of carbohydrates. However, the association was not entirely explained by the 
red meat intake. Total dietary iron, non-heme iron, or supplemental iron were not related to 
diabetes risk [71].
Other studies reveal that vegetarians have higher insulin sensitivity than omnivores, and this 
was mainly attributed to their lower body iron [72]. In this regard, blood donation, by reduc-
ing iron stores, may increase insulin sensitivity [72, 73]. However, there is controversy in this 
issue [74–76].
We have studied some cardiovascular risk markers in a population of 595 T2DM from the 
DIabetes and CArdiovascular RIsk VAllecas (DICARIVA) study according to ferritin levels 
(Table 1).
Diabetic dyslipidemia is a cluster of altered plasma lipids and lipoproteins [77] though 
LDL-cholesterol levels are normal or reduced. It is characterized by high triglycerides and 
low HDL-cholesterol levels and by increased number of small and dense LDL particles [77]. 
Altogether, these features are known as the lipidic triad. In addition, other alterations are 
often observed:
• Increased concentration of very low density lipoproteins (VLDL) due to an increased pro-
duction or a lower clearance of triglycerides and apolipoprotein (apo) B.
• Increased production of apo B-LDL as well as an increment in glycosylation and oxidation 
of LDL particles.
n Mean Standard 
deviation
P25 Median P75
Males 265 150.5 149.3 50.5 107 200.5
Females 330 67.6 83 21.8 41.5 78
The distribution of ferritin in male and femaleT2DM was significantly different (p < 0.0001).
Table 1. Male and female ferritin levels (ng/mL) in type 2 diabetes population belonging to the DIabetes and CArdiovascular 
RIsk VAllecas (DICARIVA) study P25 and P75, 25th and 75th percentiles.
Recent Trends in Cardiovascular Risks106
• Higher clearance of apo A1 with decrease in the high-size HDLs and decrease of the cho-
lesterol reverse transport.
• Lower clearance of chylomicrons and remnant particles (i.e., intermedium density lipopro-
teins or IDL).
The diabetic dyslipidemia is associated with insulin resistance, visceral obesity, and liver fat 
content. Furthermore, insulin resistance is related to an excessive flux of substrates (free fatty 
acids and glucose) to participate in the formation of VLDL in the liver and with a positive 
control of mechanisms that produces an excess of large VLDL. These lipoprotein metabolism 
anomalies are not disconnected facts but are closely related to each other [78]. It is known 
that lipid metabolism in T2DM is modulated by several factors, such as the degree of glucose 
control and insulin resistance. The hypertriglyceridemia is very prevalent in T2DM and is also 
frequent in prediabetes, preceding the presence of chronic hyperglycemia [79]. When there is 
insulin resistance, mesenteric or “central” adipocytes are full and are unable to retain more 
fatty acids, consequently fatty acids reach the liver in very high quantities.
Since LDL-size assessment requires special methodology, other approaches have been pro-
posed. The triglycerides/HDL-cholesterol molar ratio has been widely used as a surrogate 
marker of LDL-size in clinical practice [80]. Earlier a value < 1.33 for this ratio was considered 
adequate and indicative of large LDL particles. In contrast, individuals with high triglyceride/
LDL-cholesterol molar ratio present a high amount of small, dense, oxidizable, and, thus, 
highly atherogenic LDL particles [81].
It has been confirmed that triglyceridemia is the determinant of LDL size [82]. In fact, it has 
been proposed that highly enriched in triglyceride VLDL subtype (VLDL1) are the predeces-
sors of dense and small LDL particles [83].
According to the data in Table 2, T2DM women presented higher triglyceridemia and higher 
HDL-cholesterol levels but lower triglyceride/HDL-cholesterol levels than men.
This study also shows that triglyceride levels increase in parallel to the level of ferritin in men 
and women. Triglycerides were 36 and 23% higher in men and women, respectively, belong-
ing to the 4th ferritin quartile versus their 1st counterparts. LDL particles appear 38% smaller 
in men and 24% smaller in women at the highest quartile versus the lowest, according to the 
triglyceride/HDL-cholesterol molar ratio. Taking into account these data and the significant 
correlation between ferritin and this molar ratio (p < 0.001), it can be speculated that body iron 
contributes to this theoretically higher oxidability and atherogenicity of the LDL.
When the T2DM sample belonging to the 1st or 4th quartile for ferritin was stratified accord-
ing to the presence of normo or hypertriglyceridemia, low or high levels of HDL-cholesterol, 
and small or large LDL particles, it was observed that the prevalence of altered triglycerides 
was higher (odd ratio 1.78; p=0.011) in T2DM patients belonging to the highest quartile for 
ferritin. Similarly, the odd ratios for high levels of HDL-cholesterol or the presence of small 
LDLs was 0.54 (p = 0.010) and 1.93 (p = 0.004), respectively in the T2DM patients of the 4th 
quartile versus the 1st quartile of ferritin.
To insist even more in this idea, the prevalence of T2DM presenting the lipid triad was com-
pared to that of patients who did not present any of the three components of the triad. The 






N Mean SD Lower limit Upper limit ANOVA p P25 vs P75
Men Triglycerides <P25 66 128.6 63.1 113.0 144.1 0.038 0.006
mg/dL P25-<P75 133 157.8 114.3 138.2 177.4
≥P75 66 174.8 118.5 145.7 203.9
HDL-cholesterol <P25 66 48.4 12.5 45.3 51.5 0.99 0.96
mg/dL P25-<P75 133 48.6 12.7 46.4 50.7
≥P75 66 48.2 12.5 45.4 51.5
TG/HDLc* <P25 66 1.29 0.82 1.08 1.49 0.013 0.020
mol/mol P25-<P75 133 1.63 1.66 1.35 1.92
≥P75 66 1.78 1.47 1.42 2.14
Women Triglycerides <P25 82 152.8 95.4 131.9 173.8 0.027 0.17
mg/dL P25-<P75 163 138.1 101.6 122.4 153.8
≥P75 84 187.9 213.1 141.7 234.2
HDL-cholesterol <P25 82 59.2 14.9 55.9 62.4 0.025 0.007
mg/dL P25-<P75 163 56.5 14.1 54.3 58.7
≥P75 84 53.2 13.3 50.3 56.1
TG/HDLc* <P25 82 1.33 1.20 1.07 1.59 0.038 0.11
mol/mol P25-<P75 163 1.21 1.27 1.01 1.41
≥P75 84 1.65 1.40 1.35 1.96
P, percentile; ANOVA p, P value for <P25, P25-<75 and ≥P75.
*TG/HDLc, Triglycerides/HDL-cholesterol molar ratio.
Table 2. Triglyceride, HDL-cholesterol, and the Triglyceride/HDL-cholesterol molar ratio in men and women from the DIabetes and CArdiovascular RIsk VAllecas 
(DICARIVA) study stratified according to ferritin quartiles.
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concurrence of high ferritin and all the three components of the triad was higher than the con-
currence of low ferritin and the three components of the triad. On the contrary, the absence 
of any of the three components of the triad was less prevalent in T2DM patients with high 
ferritin values than in their low ferritin counterparts. The odd ratio for the lipid triad/ferritin 
association was 2.23 (p = 0.010), suggesting the hypothesis that altered CVD risk factors is 
more prevalent in T2DM patients presenting high iron body stores.
6. Conclusions, remarks, and future research
From all the above, there clearly exists a connection between iron regulation, lipoprotein 
metabolism, and insulin resistance.
Experimental evidence in animals and humans indicates that dietary fat may be impor-
tant in iron metabolism. Despite increasing evidence that dietary fat can influence iron 
absorption and retention, there is a paucity of information about the mechanism implicated 
[84, 85]. These may be related directly to changes occurring within the intestinal lumen in 
the enterocytes at luminal or apical membranes. Many aspects of iron absorption and its 
regulation are still unknown, such as the mechanisms of ferric iron transport, the role of 
mucines, and so on [8, 9, 11].
Droke et al. [86] demonstrate that palmitate increased iron transport to a greater extent 
than stearate, and this is followed by far by oleate, which could be due to fatty acid 
metabolism within the cells and the elongation of palmitic to stearic acid. However, the 
results suggest that fatty acids affected iron uptake to a greater extent than iron transport. 
One of the most striking effects of dietary fat on mineral metabolism is the finding of the 
enhancement of iron uptake and utilization by saturated fat. The effects are prominent 
when dietary iron is limiting and thus indicate a novel role in promoting an adequate iron 
status in human [86].
A genome-wide association study (GWA study or GWAS) and epigenome-wide association 
study (EWAS) together with metabolomic studies would help much to understand the mecha-
nisms involved in the conjoint iron-lipid metabolism that, in turn, affects CVD risks. This infor-
mation will be useful in the dietary personalization to optimize human health and function.
Meanwhile, as saturated fatty acids (mainly palmitic) increase the iron store [86], total cholesterol, 
and LDL cholesterol, and induce negative effects on insulin resistance compared to unsaturated 
fat [87], the authors of the present review claim insisting in the need that T2DM patients show a 
high adherence to present dietary recommendations for diabetes (American Diabetes Association 
[88]), which textually include that fat quality (eating monounsaturated and polyunsaturated fats 
and avoiding trans fats and saturated fats) appears to be more important than quantity.
In conclusion, iron is a key metal involved in cardiovascular health. Mild iron deficiency may 
reduce cardiovascular risk; contrarily, severe anemia induces alterations in the antioxidant 
iron-dependent enzymes and can be a threat. Iron overload appears to be more important 
than deficiency in triggering insulin resistance. In this regard, dysmetabolic iron overload 
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syndrome has been related to liver fat accumulation and visceral adiposity [89]. Whether 
hepcidin resistance is linked to insulin resistance should be a matter of further research.
Our data in an ample sample of adults diagnosed with T2DM suggest that body iron stores, 
evaluated as serum ferritin, are clearly related with some key markers of the so-called lipidic 
triad of the T2DM (high triglyceride and low HDL-cholesterol levels together with the presence 
of small and dense LDL particles) which also is in the frame of the dysmetabolic iron overload 
syndrome.
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